23
Jun
2009
Posted in I - Series B, Q - 2Q09, R - INTERNATIONAL, X - Biomaterial, X - Hemostasis, X - Wound Healing
LifeBond (Israel) a commercial-stage developer of wound-closure and hemostasis biomaterials, closed a $8M Series B financing. Participants include Pitango Venture Capital, GlenRock Israel and The Zitelman Group.